In GID’s randomized controlled Phase IIb trial (FDA-approved IDE trial) 88% of the patients responded greater than the placebo control and reported a median 85% improvement in pain, stiffness and function at one year.
All prespecified endpoints in the trial were met.
No serious adverse events were reported.
The treatment group was statistically significant relative to the placebo group at 6 months and at one year.